Adial Pharmaceuticals, Inc.ADILNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank71
3Y CAGR-24.0%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
-24.0%/yr
vs -1.9%/yr prior
Acceleration
-22.1pp
Decelerating
Percentile
P71
Within normal range
vs 3Y Ago
0.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 8.42% |
| Q2 2025 | 12.13% |
| Q1 2025 | -7.63% |
| Q4 2024 | 5.52% |
| Q3 2024 | 10.84% |
| Q2 2024 | 62.04% |
| Q1 2024 | -237.26% |
| Q4 2023 | -38.65% |
| Q3 2023 | -227.32% |
| Q2 2023 | 137.44% |
| Q1 2023 | -1.37% |
| Q4 2022 | 7.80% |
| Q3 2022 | 19.19% |
| Q2 2022 | -32.32% |
| Q1 2022 | 50.13% |
| Q4 2021 | -35.04% |
| Q3 2021 | 2.77% |
| Q2 2021 | 8.13% |
| Q1 2021 | -39.33% |
| Q4 2020 | -4.00% |
| Q3 2020 | -84.19% |
| Q2 2020 | 20.45% |
| Q1 2020 | -10.61% |
| Q4 2019 | -19.97% |
| Q3 2019 | 19.61% |
| Q2 2019 | 20.44% |
| Q1 2019 | -111.37% |
| Q4 2018 | 84.51% |
| Q3 2018 | -356.99% |
| Q2 2018 | -372.98% |
| Q1 2018 | 6.20% |
| Q4 2017 | -38.06% |
| Q3 2017 | -10.73% |
| Q2 2017 | -48.00% |
| Q1 2017 | -86.98% |
| Q4 2016 | 7.65% |
| Q3 2016 | -8.08% |
| Q2 2016 | 23.83% |
| Q1 2016 | 0.00% |